Deaths of 2 people linked to rare clotting disorder after AstraZeneca first doses | ABC News

ABC News (Australia) published this video item, entitled “Deaths of 2 people linked to rare clotting disorder after AstraZeneca first doses | ABC News” – below is their description.

A 44-year-old Tasmanian man and a 48-year-old Victorian woman have died after receiving the first dose of the AstraZeneca vaccine, the Therapeutic Goods Administration says.

ABC News (Australia) YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

About This Source - ABC News (Australia)

The video item below is from ABC News (Australia). ABC News is a public news service in Australia produced by the News and Current Affairs division of the Australian Broadcasting Corporation.

Recent from ABC News (Australia):

  • ‘We can’t let that happen’: Ending lockdown at 70 per cent ‘not prudent’ says Barr | ABC News
  • Tracking Australia’s COVID-19 vaccine rollout: September 18 | ABC News
  • French Ambassador leaves Canberra before departing for France | ABC News
  • In This Story: AstraZeneca

    AstraZeneca plc/AB (LON: AZN) is a British-Swedish multinational pharmaceutical and biopharmaceutical company with its headquarters in Cambridge, United Kingdom and Södertälje, Sweden. Its R&D is concentrated in Cambridge in United Kingdom, Södertälje in Sweden, and Maryland and Toronto in North America.

    3 Recent Items: AstraZeneca

  • Queensland’s ‘Super Vaccination Weekend’ kicks off | 7NEWS
  • Booster Covid vaccines to be offered to over 50s to smooth ‘bumpy’ winter
  • High demand for Pfizer vaccine sees fewer Sydneysiders come forward for AstraZeneca | 7NEWS
  • Leave a Comment

    We don't require your email address now, just your name. BUT, if you do add it, you may be notified if there are replies to your comment. Please make respectful comments, which add value, and avoid personal attacks on others. Comments failing to adhere to these guidelines will not be published.